PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-34.02%
Negative revenue growth while CVE stands at 15.12%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-49.00%
Negative gross profit growth while CVE is at 20.90%. Joel Greenblatt would examine cost competitiveness or demand decline.
-134.64%
Negative EBIT growth while CVE is at 242.22%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-134.64%
Negative operating income growth while CVE is at 242.22%. Joel Greenblatt would press for urgent turnaround measures.
-438.75%
Negative net income growth while CVE stands at 244.92%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-446.30%
Negative EPS growth while CVE is at 243.75%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-442.59%
Negative diluted EPS growth while CVE is at 243.75%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.79%
Share reduction while CVE is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.01%
Reduced diluted shares while CVE is at 0.01%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.79%
Dividend growth under 50% of CVE's 10.15%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-52.86%
Negative OCF growth while CVE is at 18.07%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-498.41%
Negative FCF growth while CVE is at 91.05%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-27.74%
Negative 10Y revenue/share CAGR while CVE stands at 58.81%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-82.67%
Negative 5Y CAGR while CVE stands at 58.81%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-69.75%
Negative 3Y CAGR while CVE stands at 20.79%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-49.52%
Negative 10Y OCF/share CAGR while CVE stands at 30.28%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-79.75%
Negative 5Y OCF/share CAGR while CVE is at 30.28%. Joel Greenblatt would question the firm’s operational model or cost structure.
144.33%
3Y OCF/share CAGR above 1.5x CVE's 8.50%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-198.61%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-588.16%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-129.29%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-11.04%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-75.05%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-73.23%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
760.15%
Dividend/share CAGR of 760.15% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-48.39%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-0.10%
Negative near-term dividend growth while CVE invests at 21.94%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-32.09%
Firm’s AR is declining while CVE shows 43.86%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-3.39%
Negative asset growth while CVE invests at 1.06%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-10.50%
We have a declining book value while CVE shows 0.23%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.36%
We’re deleveraging while CVE stands at 2.12%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-66.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.